Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.71 |
| ▸ | MAOB | P27338 | 7/20 | 0.62 |
| ▸ | MAOA | P21397 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | CALML3 | P27482 | 1/20 | 0.62 |
| ▸ | SDHA | P31040 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727001 | 1.00 | F10 (0.71) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5727254 | 0.93 | F10 (0.69) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5727245 | 0.93 | F10 (0.69) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5727147 | 0.92 | F10 (0.70) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL5727141 | 0.92 | F10 (0.70) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL8309050 | 0.90 | MAOB (0.78) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL8309053 | 0.90 | MAOB (0.78) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7256929 | 0.89 | F10 (0.67) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7256769 | 0.89 | F10 (0.67) | F10MAOBMAOALMNAPTGS1 | |
| SCHEMBL7262409 | 0.89 | F10 (0.67) | F10MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008010070-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-28 | — | — | US | disclosed |
| EP-1542696-A4 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| EP-1542696-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004014392-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | OXA1L, PDK4, SDHA | F10 1403/4885MAOB 1976/4885MAOA 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.